VJHemOnc is committed to improving our service to you

EHA 2020 | GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

VJHemOnc is committed to improving our service to you

Katja Weisel

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses an interim analysis of the GMMG-CONCEPT trial (NCT03104842), which investigated depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter